You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Carfilzomib (Kyprolis)

Showing 1 - 25 of 192
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Kyprolis® in Combination With Revlimid® and Dexamethasone or

Recruiting
  • Multiple Myeloma in Relapse
  • Frankfurt, Germany
    Centrum für Hämatologie und Onkologie Bethanien
Jun 2, 2022

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Carfilzomib, Cyclophosphamide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Jun 8, 2023

Multiple Myeloma Trial in West Hollywood, Cary (Selinexor, Placebo (for selinexor), carfilzomib)

Withdrawn
  • Multiple Myeloma
  • West Hollywood, California
  • +1 more
Jan 24, 2023

Relapsed Refractory Multiple Myeloma Trial in India (Drug: Carfilzomib + Dexamethasone, Drug: Carfilzomib + Lenalidomide +

Active, not recruiting
  • Relapsed Refractory Multiple Myeloma
  • Drug: Carfilzomib + Dexamethasone
  • Drug: Carfilzomib + Lenalidomide + Dexamethasone
  • Hyderabad, Andhra Pradesh, India
  • +16 more
Dec 13, 2022

Multiple Myeloma Trial in Detroit, Charlotte (Carfilzomib, Ruxolitinib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Detroit, Michigan
  • +1 more
Jan 27, 2023

Carfilzomib in Patients With Multiple Myeloma

Recruiting
  • Multiple Myeloma
  • Odense, Denmark
    Odense University Hospital
Dec 20, 2022

Multiple Myeloma, Relapse Multiple Myeloma Trial in Chicago (Belantamab mafodotin, Carfilzomib, Pomalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
  • Belantamab mafodotin
  • +3 more
  • Chicago, Illinois
    University of Chicago Medicine Comprehensive Cancer Center
Mar 23, 2023

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Relapsed/Refractory Multiple Myeloma Trial (Isatuximab, Carfilzomib, Dexamethasone)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • (no location specified)
Feb 3, 2023

Myeloma, Multiple Myeloma Trial in Chicago (Daratumumab, Carfilzomib, Lenalidomide)

Recruiting
  • Myeloma
  • Multiple Myeloma
  • Chicago, Illinois
    The University of Chicago
Sep 15, 2021

Multiple Myeloma Trial in Beverly Hills (Elranatamab, Carfilzomib)

Recruiting
  • Multiple Myeloma
  • Beverly Hills, California
    Beverly Hills Cancer Center
Dec 21, 2022

Multiple Myeloma Trial in Seoul (Carfilzomib 56 MG [Kyprolis], Pomalidomide, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Carfilzomib 56 MG [Kyprolis]
  • +2 more
  • Seoul, Korea, Republic of
    Samsung Medical Center
Aug 19, 2022

Multiple Myeloma Trial in Hackensack (Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
  • Hackensack, New Jersey
    Hackensack University Medical Center
Oct 4, 2021

Multiple Myeloma Trial in Little Rock (myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC

Terminated
Has Results
  • Multiple Myeloma
  • myPRS
  • +6 more
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
May 28, 2021

Multiple Myeloma Trial in United States (Isatuximab, Carfilzomib, Dexamethasone)

Recruiting
  • Multiple Myeloma
  • Isatuximab
  • +2 more
  • San Francisco, California
  • +3 more
Dec 24, 2022

Multiple Myeloma Trial in Chicago, Evanston, Ann Arbor (Elotuzumab, Carfilzomib, Lenalidomide)

Active, not recruiting
  • Multiple Myeloma
  • Chicago, Illinois
  • +2 more
Nov 12, 2021

Waldenstrom Macroglobulinemia Trial in Hackensack (Carfilzomib, Rituximab, Dexamethasone)

Completed
Has Results
  • Waldenstrom Macroglobulinemia
  • Hackensack, New Jersey
    John Theurer Cancer Center at Hackensack University Medical Cent
Mar 18, 2022

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Aug 8, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Highly Sensitized Prospective Kidney Transplant Recipients Trial in Durham (carfilzomib, belatacept, Bone marrow aspiration)

Recruiting
  • Highly Sensitized Prospective Kidney Transplant Recipients
  • carfilzomib
  • +2 more
  • Durham, North Carolina
    Duke Transplant Center, Duke University Medical Center
Jan 11, 2022

Multiple Myeloma Trial in Canada, United States (Ibrutinib, Carfilzomib, Dexamethasone)

Completed
Has Results
  • Multiple Myeloma
  • Duarte, California
  • +16 more
Nov 24, 2021

Neuroendocrine Cancer Trial in United States (Carfilzomib)

Completed
Has Results
  • Neuroendocrine Cancer
  • Denver, Colorado
  • +9 more
Jun 7, 2022

Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma Trial in Canada, United States (drug, procedure,

Active, not recruiting
Has Results
  • Stage I Multiple Myeloma
  • +2 more
  • Chicago, Illinois
  • +4 more
Sep 3, 2022

Multiple Myeloma Trial in United States (KRdD followed by auto-HCT, KRdD only)

Active, not recruiting
  • Multiple Myeloma
  • KRdD followed by auto-HCT
  • KRdD only
  • Birmingham, Alabama
  • +3 more
Mar 26, 2022

Anemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Columbus, Salt Lake City (drug, other,

Active, not recruiting
  • Anemia
  • +2 more
  • Atlanta, Georgia
  • +2 more
Jan 28, 2023